Abstract
Purpose Any available evidence regarding the application of local consolidative therapy (LCT) for oligometastases is from phase 2 and observational studies. This study aimed to evaluate the oncologic benefits of LCT in oligometastatic setting.
Methods The MEDLINE, EMBASE, and Cochrane library were searched. We applied stepwise analyses that enabled the evaluation of data from randomized controlled trials (RCTs), balanced studies (e.g. without significant differences regarding major prognosticators between arms), and all studies separately and in a hierarchical manner
Results Thirty-one studies including seven randomized trials were reviewed. Pooled analyses of the effect of LCT on overall survival (OS) revealed odds ratios (ORs) of 3.04 (95% confidence interval [CI]: 2.28–4.06, p<0.001), 2.56 (95% CI: 1.79–3.66, p<0.001), and 1.41 (95% CI: 1.02–1.95, p=0.041) for all studies, balanced studies, and RCTs, respectively. The corresponding ORs for progression-free survival were 2.82 (95% CI: 1.96– 4.06, p<0.001), 2.32 (95% CI: 1.60–3.38, p<0·001), and 1.39 (95% CI: 1.09–1.80, p=0.009), respectively. The benefit of LCT was higher in non-small cell lung cancer (OR: 3.14, p<0.001; pooled 2-year OS: 65.2% vs. 37.0%) and colorectal cancer (OR: 4.11, p=0.066; pooled two-year OS: 66.2% vs. 33.2%) than in prostate (OR: 1.87, p=0.006; pooled three-year OS: 95.6% vs. 92.6%) and small cell lung cancer (OR: 1.04, p=0.942; pooled one-year OS: 60.7% vs. 42.8%). Complications were generally mild.
Conclusion LCT provides oncologic benefits in the oligometastatic setting, although such benefits were less evident in RCTs than in data from observational studies. The appropriate LCTs should be carefully selected, considering their feasibility and disease types.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Research Fund of Korea (NRF-2019M2D2A1A01031560). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was not required because this study retrieved and synthesized data that are already published.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email address of authors: CH Rim, crusion3{at}naver.com; IS Shin, 9065031{at}hanmail.net; S Park, sunmini815{at}gmail.com; HY Lee, heygemma{at}korea.ac.kr
Data Availability
N/A
